Relmada targets year-end IND filings for NDV-01 and sepranolone, reports $217.7M cash
The company said it expects to submit INDs for both lead programs by year-end 2026, with cash it says can fund operations through 2029.
SEC filing
Latest
2 stories
Thursday, August 6
Tuesday, July 28
Relmada names Bipin Dalmia as Chief Business Officer
The clinical-stage biotech brought on the former Ferring uro-oncology executive to help guide strategy for its bladder cancer therapy NDV-01.
SEC filing